The prognosis of HR + breast cancer patients was previously thought to be the best among all subtypes of breast cancer; however, with the development of anti-HER2 targeted therapy for HER2 + breast cancer and intensive therapy for triple-negative breast cancer, the prognostic advantage of HR + early breast cancer patients is no longer obvious. Here, ERBB2 is linked to triple-negative breast carcinoma.